- Home
- ELLO vs ZNTL Comparison
ELLO vs ZNTL Comparison
Compare ELLO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$4.00
Company Overview
Basic Information| Metric | ELLO | ZNTL |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.7M | 289.0M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ELLO | ZNTL |
|---|---|---|
| Price | $19.08 | $4.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 7.4K | ★ 811.4K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.40 | $1.13 |
| 52 Week High | $30.34 | $6.95 |
Technical Indicators
Market Signals| Indicator | ELLO | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 27.71 | 56.10 |
| Support Level | $16.94 | $3.45 |
| Resistance Level | $19.66 | $4.38 |
| Average True Range (ATR) | 0.80 | 0.27 |
| MACD | -0.21 | 0.04 |
| Stochastic Oscillator | 0.00 | 91.68 |
Price Performance
Historical Comparison ELLO
ZNTL
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.